CN102686738A - 通过改进的a蛋白洗脱增强的蛋白质纯化 - Google Patents

通过改进的a蛋白洗脱增强的蛋白质纯化 Download PDF

Info

Publication number
CN102686738A
CN102686738A CN2010800389895A CN201080038989A CN102686738A CN 102686738 A CN102686738 A CN 102686738A CN 2010800389895 A CN2010800389895 A CN 2010800389895A CN 201080038989 A CN201080038989 A CN 201080038989A CN 102686738 A CN102686738 A CN 102686738A
Authority
CN
China
Prior art keywords
polypeptide
protein
gradient
elution
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800389895A
Other languages
English (en)
Chinese (zh)
Inventor
A·布朗
C·J·多德
A·N·拉达莫汉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43649614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102686738(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to CN201810100462.9A priority Critical patent/CN108409829A/zh
Publication of CN102686738A publication Critical patent/CN102686738A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN2010800389895A 2009-09-01 2010-09-01 通过改进的a蛋白洗脱增强的蛋白质纯化 Pending CN102686738A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810100462.9A CN108409829A (zh) 2009-09-01 2010-09-01 通过改进的a蛋白洗脱增强的蛋白质纯化

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23886709P 2009-09-01 2009-09-01
US61/238,867 2009-09-01
US25343809P 2009-10-20 2009-10-20
US61/253,438 2009-10-20
PCT/US2010/047448 WO2011028753A1 (en) 2009-09-01 2010-09-01 Enhanced protein purification through a modified protein a elution

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810100462.9A Division CN108409829A (zh) 2009-09-01 2010-09-01 通过改进的a蛋白洗脱增强的蛋白质纯化

Publications (1)

Publication Number Publication Date
CN102686738A true CN102686738A (zh) 2012-09-19

Family

ID=43649614

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010800389895A Pending CN102686738A (zh) 2009-09-01 2010-09-01 通过改进的a蛋白洗脱增强的蛋白质纯化
CN201810100462.9A Pending CN108409829A (zh) 2009-09-01 2010-09-01 通过改进的a蛋白洗脱增强的蛋白质纯化

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201810100462.9A Pending CN108409829A (zh) 2009-09-01 2010-09-01 通过改进的a蛋白洗脱增强的蛋白质纯化

Country Status (14)

Country Link
US (3) US9428548B2 (enExample)
EP (2) EP2473617B1 (enExample)
JP (1) JP5787891B2 (enExample)
KR (1) KR101764449B1 (enExample)
CN (2) CN102686738A (enExample)
BR (1) BR112012004697B8 (enExample)
CA (1) CA2772653C (enExample)
ES (1) ES2787234T3 (enExample)
HR (1) HRP20200581T1 (enExample)
MX (1) MX2012002565A (enExample)
PL (1) PL2473617T3 (enExample)
RU (1) RU2571929C2 (enExample)
SI (1) SI2473617T1 (enExample)
WO (1) WO2011028753A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105073769A (zh) * 2013-03-14 2015-11-18 Emd密理博公司 利用基于a蛋白的色谱增加蛋白纯度的方法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
CN103276033A (zh) 2006-09-13 2013-09-04 雅培制药有限公司 细胞培养改良
CN105111309A (zh) 2008-10-20 2015-12-02 Abbvie公司 使用a蛋白亲和层析分离和纯化抗体
CN104974251A (zh) 2008-10-20 2015-10-14 Abbvie公司 在抗体纯化过程中的病毒灭活
PT2462158T (pt) 2009-08-06 2018-02-23 H Hoffnabb La Roche Ag Método para melhorar a remoção de vírus na purificação de proteínas
ES2526876T3 (es) * 2009-09-10 2015-01-16 Lonza Biologics Plc. Método y sistema para purificación de polipéptidos
HRP20181846T1 (hr) * 2011-12-22 2018-12-28 Genentech, Inc. Kromatografija membranom za ionsku izmjenu
WO2013147691A1 (en) * 2012-03-28 2013-10-03 Ge Healthcare Bio-Sciences Ab Affinity chromatography matrix
SG11201406407TA (en) 2012-06-29 2014-11-27 Emd Millipore Corp Methods for inactivating viruses during a protein purification process
US8921113B2 (en) 2012-12-21 2014-12-30 Dionex Corporation Buffer kit and method of generating a linear pH gradient
CN105377873B (zh) * 2013-07-12 2021-03-30 豪夫迈·罗氏有限公司 阐明离子交换层析输入优化
MX380902B (es) * 2013-11-15 2025-03-12 Genentech Inc Métodos para la inactivación viral usando detergentes ecológico.
EP3674310A1 (en) * 2014-03-10 2020-07-01 Richter Gedeon Nyrt. Immunoglobulin purification using pre-cleaning steps
GB2539420B (en) * 2015-06-16 2021-01-13 Cytiva Sweden Ab Determination of chromatography conditions
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
CN112566930A (zh) * 2018-06-19 2021-03-26 百时美施贵宝公司 使用色谱纯化蛋白质的方法
US11022585B2 (en) 2019-06-09 2021-06-01 Dionex Corporation Methods and systems for optimizing buffer conditions with liquid chromatography
CA3167669A1 (en) * 2020-01-17 2021-07-22 Regeneron Pharmaceuticals, Inc. Hydrophobic interaction chromatography for viral clearance
KR20250011797A (ko) 2023-07-13 2025-01-22 주식회사 녹십자 알부민이 융합된 단백질의 정제방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008025747A1 (en) * 2006-08-28 2008-03-06 Ares Trading S.A. Process for the purification of fc-fusion proteins
US20080167450A1 (en) * 2007-01-05 2008-07-10 Hai Pan Methods of purifying proteins

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
ES2058199T3 (es) 1987-09-23 1994-11-01 Bristol Myers Squibb Co Heteroconjugados de anticuerpos para la eliminacion de celulas infectadas por el vih.
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
EP0420937B1 (en) 1988-06-21 1994-11-09 Genentech, Inc. Therapeutic compositions for the treatment of myocardial infarction
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
EP0420397B1 (en) 1989-07-28 1995-11-29 Wako Pure Chemical Industries Ltd Fulgimide derivatives
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
EP1260521B1 (en) 1991-08-14 2007-11-21 Genentech Inc. Immunoglobulin variants for specific Fc epsilon receptors
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP1997894B1 (en) 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
ATE161192T1 (de) 1992-08-21 1998-01-15 Genentech Inc Verfahren zur behandlung einer durch lfa-1 vermittelten störung
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
ES2108566T3 (es) 1993-12-10 1997-12-16 Genentech Inc Procedimientos para diagnosticar alergias y para seleccionar agentes terapeuticos antialergicos.
ATE164079T1 (de) 1994-01-18 1998-04-15 Genentech Inc Verfahren zur behandlung von parasitären infektionen unter verwendung von ige-antagonisten
US5707622A (en) 1994-03-03 1998-01-13 Genentech, Inc. Methods for treating ulcerative colitis
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
WO1996040210A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
EP1297847A3 (en) 1996-01-23 2003-05-07 Genentech, Inc. Anti-CD18 antibodies in stroke
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
ATE267257T1 (de) 1996-11-27 2004-06-15 Genentech Inc Humanisierte anti-koerper gegen cd11a
US20030109680A1 (en) 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
ES2273415T3 (es) 1997-04-07 2007-05-01 Genentech, Inc. Anticuerpos anti-vegf.
ATE516354T1 (de) 1997-05-15 2011-07-15 Genentech Inc Apo-2-rezeptor
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
RU2145610C1 (ru) 1998-12-09 2000-02-20 Общество с ограниченной ответственностью "Протеиновый контур" Способ очистки рекомбинантного эритропоэтина человека
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
PL203326B1 (pl) 1999-06-25 2009-09-30 Genentech Inc Przeciwciało, kompozycja farmaceutyczna, koniugat, izolowany kwas nukleinowy, wektor, komórka gospodarza i sposób wytwarzania przeciwciała
CA2387108A1 (en) 1999-10-29 2001-06-07 Genentech, Inc. Anti-prostate stem cell antigen (psca) antibody compositions and methods of use
AU2003272454A1 (en) * 2002-09-18 2004-04-08 Genencor International, Inc. Protein purification
CN101120017A (zh) * 2004-08-30 2008-02-06 英国龙沙生物医药股份有限公司 用于纯化抗体的亲和力加离子交换层析
EP1693108A1 (en) * 2004-12-04 2006-08-23 MERCK PATENT GmbH Mixed-modal anion-exchange type separation material
CA2611815A1 (en) * 2005-06-17 2006-12-28 Elan Pharma International Limited Methods of purifying anti a beta antibodies
BRPI0806367A2 (pt) 2007-01-22 2011-09-06 Genentech Inc métodos de purificação de anticorpos
CN105111309A (zh) * 2008-10-20 2015-12-02 Abbvie公司 使用a蛋白亲和层析分离和纯化抗体
ES2865648T3 (es) * 2009-06-26 2021-10-15 Regeneron Pharma Anticuerpos biespecíficos fácilmente aislados con formato de inmunoglobulina nativa
JP5731726B1 (ja) 2014-06-26 2015-06-10 楽天株式会社 情報処理装置、情報処理方法及び情報処理プログラム

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008025747A1 (en) * 2006-08-28 2008-03-06 Ares Trading S.A. Process for the purification of fc-fusion proteins
US20080167450A1 (en) * 2007-01-05 2008-07-10 Hai Pan Methods of purifying proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PAN H等: "Quantitation of soluble aggregates in recombinant monoclonal antibody cell culture by pH-gradient protein A chromatography", 《ANALYTICAL BIOCHEMISTRY》, vol. 388, 15 May 2009 (2009-05-15), pages 273 - 278, XP026051999, DOI: 10.1016/j.ab.2009.02.037 *
RECNY等: "N-Glycosylation is required for Human CD2 immunoadhesion functions.", 《JOURNAL OF BIOLOGY AND CHEMISTRY》, vol. 267, no. 31, 31 December 1992 (1992-12-31), pages 22428 - 22434, XP055011435 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105073769A (zh) * 2013-03-14 2015-11-18 Emd密理博公司 利用基于a蛋白的色谱增加蛋白纯度的方法
CN105073769B (zh) * 2013-03-14 2019-09-10 Emd密理博公司 利用基于a蛋白的色谱增加蛋白纯度的方法
US10472389B2 (en) 2013-03-14 2019-11-12 Emd Millipore Corporation Methods of increasing protein purity using protein A based chromatography

Also Published As

Publication number Publication date
JP2013503877A (ja) 2013-02-04
HRP20200581T1 (hr) 2020-07-10
JP5787891B2 (ja) 2015-09-30
CN108409829A (zh) 2018-08-17
RU2571929C2 (ru) 2015-12-27
CA2772653C (en) 2019-06-25
BR112012004697B8 (pt) 2021-05-25
EP2473617A1 (en) 2012-07-11
BR112012004697B1 (pt) 2021-02-09
PL2473617T3 (pl) 2020-06-29
WO2011028753A1 (en) 2011-03-10
BR112012004697A2 (pt) 2015-09-08
EP3736338A1 (en) 2020-11-11
US20220081466A1 (en) 2022-03-17
US9428548B2 (en) 2016-08-30
US20220324905A1 (en) 2022-10-13
SI2473617T1 (sl) 2020-07-31
EP2473617A4 (en) 2014-04-09
ES2787234T3 (es) 2020-10-15
RU2012112536A (ru) 2013-10-10
US20130041139A1 (en) 2013-02-14
CA2772653A1 (en) 2011-03-10
EP2473617B1 (en) 2020-02-26
KR101764449B1 (ko) 2017-08-02
KR20120106719A (ko) 2012-09-26
MX2012002565A (es) 2012-05-29

Similar Documents

Publication Publication Date Title
US20220081466A1 (en) Enhanced protein purification through a modified protein a elution
KR101036414B1 (ko) 이온 교환 크로마토그래피에 의한 단백질 정제 방법
DK1501369T3 (en) Non-affinity purification of proteins
CA2531595C (en) Reducing protein a leaching during protein a affinity chromatography
US7452539B2 (en) Stabilizing polypeptides which have been exposed to urea
MX2011001506A (es) Metodos para eliminar un contaminante utilizado cromatografia de membrana de intercambio de ion en desplazamiento de proteina indigena.
HK1174666A (en) Enhanced protein purification through a modified protein a elution
HK1233270A1 (en) Reducing protein a leaching during protein a affinity chromatography
HK1194082A (en) Antibody purification by cation exchange chromatography
AU2011253773A1 (en) Reducing protein a leaching during protein a affinity chromatography

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1174666

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20120919

RJ01 Rejection of invention patent application after publication